|
Market Closed -
Nasdaq
01:30:00 02/10/2026 am IST
|
5-day change | 1st Jan Change | ||
| 46.99 USD | -22.39% |
|
-20.87% | +11.14% |
| 07:20pm | Nektar Therapeutics - Shareholder/Analyst Call | |
| 01/10 | Nektar Therapeutics Presents New Results From Multi-Omic Biomarker Sub-Study From REZOLVE-AD | CI |
| Market Cap | 206.72Cr 183.61Cr 171.7Cr 156.47Cr 294.58Cr 20TCr 298.63Cr 2.08TCr 804.12Cr 10TCr 776.13Cr 759.3Cr 33TCr | P/E 2026 * |
-7.49x | P/E 2027 * | -5.91x |
|---|---|---|---|---|---|
| Enterprise Value | 197.92Cr 175.79Cr 164.39Cr 149.81Cr 282.03Cr 19TCr 285.91Cr 1.99TCr 769.88Cr 9.7TCr 743.08Cr 726.97Cr 31TCr | EV / Sales 2026 * |
47.3x | EV / Sales 2027 * | 32.6x |
| Free-Float |
99.62% | Yield 2026 * |
-
| Yield 2027 * | - |
| Markets | Quality | ||
|---|---|---|---|
Nasdaq
| NKTR | Delayed | |
CBOE
| NKTR | Real-time | |
|
Tradegate
| ITH0 | Real-time | |
|
Boerse Muenchen
| ITH0 | Real-time | |
|
Xetra
| ITH0 | Delayed | |
|
Deutsche Boerse AG
| ITH0 | Delayed | |
|
Börse Stuttgart
| ITH0 | Delayed |
Last Transcript: Nektar Therapeutics
| 1 day | -22.39% | ||
| 1 week | -20.87% | ||
| Current month | -22.39% | ||
| 1 month | -34.51% | ||
| 3 months | -27.02% | ||
| 6 months | -37.93% | ||
| Current year | +11.14% |
| 1 week | 46.29 |  | 62.4 |
| 1 month | 46.29 | | 77.76 |
| Current year | 33.4 | | 109 |
| 1 year | 33.4 | | 109 |
| 3 years | 6.19 | | 109 |
| 5 years | 6.19 | | 280.35 |
| 10 years | 6.19 | | 1,670.4 |
| Manager | Title | Age | Since |
|---|---|---|---|
Howard Robin
CEO | Chief Executive Officer | 73 | 01/01/2007 |
Linda Rubinstein
DFI | Director of Finance/CFO | 60 | 15/05/2026 |
| Chief Tech/Sci/R&D Officer | 52 | 01/07/2015 |
| Director | Title | Age | Since |
|---|---|---|---|
Roy Whitfield
BRD | Director/Board Member | 72 | 01/08/2000 |
Robert Chess
CHM | Chairman | 69 | 01/05/1992 |
Howard Robin
BRD | Director/Board Member | 73 | 01/02/2007 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 23/09/26 | Free | Director | 6,000 | 0.0176% | ||
| 23/09/26 | Free | Director | 6,000 | 0.0176% | ||
| 23/09/26 | Free | Director | 6,000 | 0.0176% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -22.39% | -20.87% | -20.15% | +449.69% | 206.72Cr | |
| +4.16% | -0.36% | +49.37% | +94.17% | 7.45TCr | |
| -0.61% | +0.69% | +36.36% | +82.72% | 6.01TCr | |
| -2.54% | -0.21% | +6.34% | +31.72% | 4.82TCr | |
| -3.02% | -5.20% | +27.94% | +34.47% | 4.43TCr | |
| +0.31% | +3.02% | +348.95% | +686.74% | 4.4TCr | |
| -1.96% | -0.33% | +7.04% | +100.99% | 4.16TCr | |
| +3.32% | +3.49% | +11.18% | +51.23% | 3TCr | |
| +4.77% | +6.16% | +36.77% | +22.78% | 2.93TCr | |
| -4.86% | -10.66% | -26.27% | +328.03% | 2.49TCr | |
| Average | -2.28% | +2.27% | +47.75% | +188.25% | 3.99TCr | |
| Weighted average by Cap. | +0.06% | +1.85% | +59.58% | +152.34% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 4.19Cr 3.72Cr 3.48Cr 3.17Cr 5.97Cr 403.2Cr 6.05Cr 42Cr 16Cr 205.34Cr 16Cr 15Cr 659.55Cr | 5.7Cr 5.06Cr 4.73Cr 4.31Cr 8.12Cr 548.77Cr 8.23Cr 57Cr 22Cr 279.48Cr 21Cr 21Cr 897.66Cr |
| Net income | -24Cr -22Cr -20Cr -19Cr -35Cr -2.36TCr -35Cr -245.86Cr -95Cr -1.2TCr -92Cr -90Cr -3.85TCr | -35Cr -31Cr -29Cr -27Cr -50Cr -3.41TCr -51Cr -355.46Cr -137.6Cr -1.73TCr -132.81Cr -129.93Cr -5.57TCr |
| Net Debt | -8.8Cr -7.82Cr -7.31Cr -6.66Cr -13Cr -847.45Cr -13Cr -88Cr -34Cr -431.59Cr -33Cr -32Cr -1.39TCr | -21Cr -19Cr -17Cr -16Cr -30Cr -2.03TCr -30Cr -211.39Cr -82Cr -1.03TCr -79Cr -77Cr -3.31TCr |
| Date | Price | Change | Volume |
|---|---|---|---|
| 02/26/02 | $46.99 | -22.39% | 62,42,720 |
| 30/26/30 | $60.55 | +2.20% | 12,10,000 |
| 29/26/29 | $59.24 | -1.92% | 18,16,418 |
| 28/26/28 | $60.40 | +5.85% | 13,76,161 |
| 25/26/25 | $57.06 | -3.91% | 26,36,139 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- NKTR Stock
Select your edition
All financial news and data tailored to specific country editions
